Interview: The ASX-listed company working to beat a devastating disease
FEAR & GREED | Business News
<p>Alterity Therapeutics is an ASX-listed company that’s focused on developing treatments for devastating conditions like Parkinson’s disease and Multiple System Atrophy. </p>
<p>And it’s a long way down the path with one of its treatments, having just completed its phase two clinical trial.</p>
<p>Dr David Stamler, Chief Executive of Alterity Therapeutics, talks to Sean Aylmer about the path to developing new treatments, and what a successful treatment would mean for patients.</p>
<p> </p>
<p><em>Alterity Therapeutics is a supporter of Fear & Greed</em></p>
<p><a href="https://fearandgreed.com.au" rel="nofollow">Find out more: https://fearandgreed.com.au</a></p>
<p>See <a href="https://omnystudio.com/listener" rel="nofollow">omnystudio.com/listener</a> for privacy information.</p>